Biotech and Pharma

Eli Lilly reports fourth-quarter earnings and revenue that handily top expectations and issues solid guidance.

AbbVie posts better-than-expected earnings but revenue declines across certain business lines.

Forgent Power Solutions, Liftoff Mobile and several consumer and biotech firms are set to go public.

The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts’ forecasts.

AMD’s data center sales boost quarter above expectations, Fed governor Miran gives up White House post, PepsiCo is accelerating affordability initiatives, and more news to start your day.

Palantir stock rises on the back of better-than-expected quarterly earnings and a solid first-quarter outlook.

Shares of Sagimet Biosciences were up as much as 12% after encouraging clinical trial results for its acne treatment.

Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.

Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Strategy, Coinbase and Robinhood stocks tumble after the price of Bitcoin drops to a 10-month low.

Seagate Technology shares surge after the hard-disk-drive maker beats analysts’ fourth-quarter earnings estimates.

Merck, which reports Feb. 3, looks especially compelling.

Elevance stock tumbled after the Trump administration proposed keeping Medicare rates roughly flat in 2027.

CEO Robert Ford made his first purchase of company stock since March.

The Trump administration proposed keeping Medicare rates roughly flat this year.

USA Rare Earth surges on a government investment, while CoreWeave jumps following an announcement that Nvidia is making a $2 billion investment in the AI cloud company.

Sarepta’s blockbuster gene therapy has come under scrutiny following a string of patient deaths.

The two pharmaceutical makers had been in talks around a deal.

The deal for Penumbra will pay off in the long run. Hang on to the shares.

Intel shares plummet following disappointing guidance, while rival AMD is poised to add to an eight-day winning streak.

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.

Intel shares traded flat ahead of the chip maker’s fourth-quarter earnings, due out after the close of trading Thursday.

Wall Street is hopeful that a pipeline of cancer drugs can drive earnings growth as the respiratory vaccine business flounders.

Intel surges toward a four-year high ahead of earnings, while Netflix declines after issuing weaker-than-expected margin guidance.

The pharma giant’s shares rose 43% in 2025, making it their best year in three decades.